UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at http://www.ucl.ac.uk/finance/research/post_award/post_award_contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Dr Hayley Pye
Wing 2.4
Cruciform Building
Gower Street
London
WC1E 6BT
Appointment
  • Research Associate
  • Department of Tissue & Energy
  • Div of Surgery & Interventional Sci
  • Faculty of Medical Sciences
Biography

I obtained my BSc in Biochemistry at the University of Manchester, shortly followed by a PhD with Dr M.Deonarain and a biotechnology company called Photobiotics developing new drugs for Photodynamic therapy. While writing my thesis I undertook a brief 6 month placement at ETH Zurich in Switzerland under Prof. D.Neri to study antibody fragment re-engineering. This was followed with 3 years as a postdoctoral research associate at University College London with Prof. L.Lovat developing biomarker targeted antibody based drug conjugates for photodynamic therapy in oesophageal cancer. I am now part of the Whitaker group and am focused on the clinical validation of new fluid biomarkers for prostate cancer, I am working to develop better non-invasive biopsy techniques to be used in combination with MRI imaging for improved diagnosis and prognosis of prostate cancer.

Research Summary

In my current project we want to use novel, non-invasive and inexpensive blood and urine tests to rationalise selection of patients with prostate cancer, this will improve the diagnosis and prognosis of patients with prostate cancer at an early stage. Reducing the amount of men who have to live with a ‘no mans land’ diagnosis i.e. somewhere between ‘unlikely to have’ and ‘certain to have’ cancer. It will also increase the amount of men who have access to MRI based diagnosis techniques – currently restricted due to NHS economics. We are trying to work in such a way that the ‘pathway’ we develop for the clinical evaluation of emerging fluidic markers in prostate cancer will translate quickly and directly into clinical practice. Trying to more efficiently connect academic discovery to actual patient benefit is very motivating.

Please report any queries concerning the data shown on this page to https://www.ucl.ac.uk/hr/helpdesk/helpdesk_web_form.php
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by